{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:01:40Z","timestamp":1770508900748,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T00:00:00Z","timestamp":1186358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interferon alpha is used for the adjuvant treatment of malignant melanoma at different dosages (high\u2010, intermediate\u2010, low\u2010dose therapy). Only a minority of patients might benefit from this therapy, and markers to identify such patients are missing. A recent study suggested that melanoma patients developing autoantibodies or clinical manifestations of autoimmunity during adjuvant<jats:italic>high\u2010dose<\/jats:italic>interferon alpha treatment had a significant survival benefit. We retrospectively reviewed 134 melanoma patients from our institution treated with adjuvant<jats:italic>low\u2010dose<\/jats:italic>interferon alpha therapy and correlated the development of autoimmune diseases with prognosis. Interferon (IFN) therapy was routinely monitored by history, physical examination and laboratory tests before, after the first month and then after every 3 months of therapy. During a median follow up of 46.0 months (8.5\u201379.0 months) 28 patients (20.9%) suffered from recurrences and melanoma related deaths occurred in 16 patients (11.9%). In 20 patients (14.9%) autoimmune thyroiditis (AIT) was diagnosed during IFN therapy, one of these 20 patients developed rheumatoid arthritis later while continuing IFN therapy. Other autoimmune diseases were not observed. In 2 patients (one with AIT and one with arthritis) the autoimmune disease led to discontinuation of IFN therapy, in the other patients AIT remained subclinical or responded well to treatment while IFN therapy was continued. Kaplan\u2013Meier analyses revealed a significant better recurrence free survival and a trend for a better overall survival for patients with AIT. Thus, autoimmunity triggered by low\u2010dose IFN therapy appears to indicate an improved prognosis and should encourage continuation of IFN therapy. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.22951","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T14:17:01Z","timestamp":1186409821000},"page":"2562-2566","source":"Crossref","is-referenced-by-count":28,"title":["Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low\u2010dose interferon alpha"],"prefix":"10.1002","volume":"121","author":[{"given":"Imke","family":"Satzger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Schenck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1103-3"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1425"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67482-X"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21760"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-41708"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000075046"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21146"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80304-7"},{"key":"e_1_2_6_10_2","first-page":"533","article-title":"Autoimmune mediated thrombocytopenia associated with the use of interferon\u2010alpha in chronic myeloid leukemia","volume":"81","author":"Zuffa E","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940315)73:6<1621::AID-CNCR2820730613>3.0.CO;2-E"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.6.393"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1177"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(99)80095-X"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053007"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2002.01512.x"},{"issue":"1","key":"e_1_2_6_17_2","first-page":"S30","article-title":"[Malignant melanoma. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V.]","volume":"48","author":"Kaufmann R","year":"1998","journal-title":"Hautarzt"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3635"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/archderm.1987.01660320095019","article-title":"Prognostic significance of hypopigmentation in malignant melanoma","volume":"123","author":"Bystryn JC","year":"1987","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(83)70182-9"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3477"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.529"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000057631"},{"key":"e_1_2_6_24_2","first-page":"367","article-title":"Development of autoimmune thyroid diseases during long\u2010term treatment of hematological malignancies with alpha\u2010interferons","volume":"79","author":"Silvestri F","year":"1994","journal-title":"Haematologica"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried MW","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.21.2371"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8182"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/105072503322238809"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.22951","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.22951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:28:53Z","timestamp":1737347333000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.22951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,6]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1002\/ijc.22951"],"URL":"https:\/\/doi.org\/10.1002\/ijc.22951","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,6]]}}}